<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="bjh15459-fig-0003" orientation="portrait" position="float">
 <label>Figure 3</label>
 <caption>
  <p>Descriptive plots for the exploratory analysis showing the subscales; Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning. For the intensive pathway (A), non‚Äêintensive pathway (B) and maintenance phase (C). These graphs present the mean subscale scores and approximate 95% confidence intervals at each time point by the variable of interest for the four key subscales in complete case data. Note that Pain and Fatigue are worse with higher scores whereas Global Health Status/Quality of Life and Physical Functioning are better with higher scores. 
   <styled-content style="fixed-case">CTD</styled-content>, cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CTD</styled-content>a, attenuated cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CVAD</styled-content>, cyclophosphamide, vincristine, doxorubicin and dexamethasone; MP, melphalan and prednisolone.
  </p>
 </caption>
 <graphic id="nlm-graphic-5" xlink:href="BJH-182-816-g003" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
